Evropska unija - slovenščina - EMA (European Medicines Agency)

theravia - holinska kislina - digestive system diseases; metabolism, inborn errors - Žolčnih kislin in derivati - orphacol je indicirano za zdravljenje prirojenih napak v primarni sintezo žolčnih kislin zaradi oxidoreductase 3β-hidroksi-Δ5-c27-steroid pomanjkljivost ali Δ4-3-oxosteroid-5β-reduktazo pomanjkljivost pri dojenčkih, otrocih in mladostnikih v starosti enega meseca do 18 let in odrasli.

Evropska unija - slovenščina - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinurija, paroksizmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamid - epilepsija - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ucb pharma s.a. - lakosamid - epilepsije, delno - antiepileptics, - lacosamide ucb je označen kot monotherapy in adjunctive terapija pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev pri odraslih, mladostnikih in otrocih od 4 let z epilepsijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamid - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - simvastatin - filmsko obložena tableta - simvastatin 40 mg / 1 tableta - simvastatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - simvastatin - filmsko obložena tableta - simvastatin 40 mg / 1 tableta - simvastatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - simvastatin - filmsko obložena tableta - simvastatin 20 mg / 1 tableta - simvastatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - simvastatin - filmsko obložena tableta - simvastatin 10 mg / 1 tableta - simvastatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intervet international bv wim de körverstraat 35 5831 an boxmeer nizozemska proizvajalec -